UCB and Sanofi-Aventis laud oral Xyzal
19 February 2008 00:00 in Pharmaceutical Company Product News
UCB and Sanofi-Aventis have reported that the oral solution of Xyzal (levocetirizine dihydrochloride) offers patients who dislike pills or have problems swallowing a new alternative to treat their allergies.
The companies had entered into a partnership agreement in September 2006 to launch and co-market Xyzal, with both firms boasting a long history in the field of allergy treatments and both claiming to be dedicated to helping meet previously unmet clinical needs in this area.
A new drug application for a 0.5 mg/ml oral solution of Xyzal has this week been approved by the US Food and Drug Administration to treat chronic idiopathic urticaria and relieve the symptoms of outdoor and indoor allergies.
Michael S Blaiss, clinical professor of paediatrics and medicine at the University of Tennessee Health Science Centre, said: "The oral solution of Xyzal provides a welcome alternative for those patients who have difficulty swallowing or who prefer liquid medication."
He added that both the tablet and oral solution forms of the drug offer patients long-lasting and powerful relief from the symptoms of their allergies.
In 2006, Schering-Plough announced that a study published in the October issue of Drug Safety found that the administration of Aerius/Neoclarityn (desloratadine) results in less chance of drowsiness than treatment with Xyzal.
Other news stories from 19/02/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency